The new 2024 European guideline on chronic coronary syndromes (CCS) is a pivotal document for clinical practice, updating the evidence and indications after five years, incorporating insights from the paradigm-shifting ISCHEMIA trial. This article explores the evolving role of functional and anatomical testing in assessing coronary artery disease (CAD), highlighting the introduction of a new risk probability score based on clinical and risk factors. Additionally, it provides a detailed comparison between these European recommendations and those from the most influential American guidelines, emphasizing key differences in the approach to risk stratification and diagnostic strategies. This comprehensive analysis provides valuable insights for optimizing the management of a syndrome that, in light of new evidence, has proven to be clinically complex and, in many aspects, counterintuitive.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892725 | PMC |
| http://dx.doi.org/10.37616/2212-5043.1416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global research trends and hotspots in mitochondria and asthma: A bibliometric and visualized analysis.
J Asthma
March 2025
Department of Pediatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Article Synopsis
- Asthma is a chronic respiratory disease involving inflammation and other respiratory issues, with mitochondria playing a crucial role in its underlying mechanisms.
- A bibliometric analysis of research from 2004 to mid-2024 identified 669 publications, showing significant growth in studies since 2015, primarily from the US, China, and the UK.
- Key themes include mitochondrial dysfunction and oxidative stress, with emerging research focusing on mitochondrial biogenesis and the NLRP3 inflammasome, suggesting opportunities for new therapeutic strategies targeting mitochondria in asthma treatment.
In the 55th meeting of the Codex Committee on Pesticide Residues (CCPR meeting) held in June 2024 and the subsequent 47th meeting of the Codex Alimentarius Commission (CAC) (November 2024), in total 111 Codex MRLs (CXLs) for 16 active substances (a.s.) were revoked.
View Article and Find Full Text PDFIschemia and Anatomy in the New 2024 European Guidelines for Chronic Coronary Syndromes: Update and Comparison of Recommendations.
J Saudi Heart Assoc
January 2025
Médica MIA Hospital, International Cardiovascular Medicine Clinic, Lerma, Mexico.
The new 2024 European guideline on chronic coronary syndromes (CCS) is a pivotal document for clinical practice, updating the evidence and indications after five years, incorporating insights from the paradigm-shifting ISCHEMIA trial. This article explores the evolving role of functional and anatomical testing in assessing coronary artery disease (CAD), highlighting the introduction of a new risk probability score based on clinical and risk factors. Additionally, it provides a detailed comparison between these European recommendations and those from the most influential American guidelines, emphasizing key differences in the approach to risk stratification and diagnostic strategies.
View Article and Find Full Text PDFPreoperative Management of Catecholamine-Producing Pheochromocytomas and Paragangliomas-Results From a DELPHI Process.
J Endocr Soc
March 2025
Department of Internal Medicine IV, University Hospital Munich, Munich 80336, Germany.
Context: European and German consensus guidelines advocate preoperative therapy with α-adrenoreceptor antagonists in symptomatic patients with catecholamine-producing pheochromocytomas and paragangliomas (PPGLs) to avoid hypertensive crisis during adrenalectomy. This practice has been questioned recently.
Objective: This work aimed to assess current preoperative management of PPGLs across disciplines.
Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024.
Front Allergy
February 2025
Department of Allergy & Rhinology, Royal National ENT Hospital, London, United Kingdom.
Article Synopsis
- In April 2024, the European Summit on chronic respiratory diseases (CRDs) was held in the European Parliament, organized by EUFOREA and hosted by MEPs Dorien Rookmaker and Mislav Kolakušić.
- The Summit aimed to address the challenges faced by European patients with CRDs by fostering collaboration among various European and global health organizations.
- Representatives from multiple societies and patient associations discussed strategies to improve respiratory care and prevention by sharing their visions and action plans.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!